The Cost Of A Cure: Gilead Exec Outlines Factors In Sovaldi’s Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead Science Executive VP Gregg Alton defended Sovaldi’s pricing at an AEI event July 11, the same day Senators Wyden and Grassley sent a letter requesting detailed information on the company’s investment in the drug and how it set the price.